Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. 

Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development.

Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Kymera Therapeutics

CRISPR Therapeutics

J.P. Morgan Securities Inc.

Bank of America Merrill Lynch

Morgan Stanley

Goldman Sachs

Janssen Belgium

Norwest Venture Partners

J.H. Whitney & Co

New Enterprise Associates

Greylock

Vertex Pharmaceuticals

Join us in welcoming Lateefah Spires Brown the new San Diego Learning Lab head, to the Vertex team. 

A lifelong educator, Lateefah has a background in biology and a love for all things science — as a child you could even find her scooping up tadpoles and catching fireflies. 

While it was tough for Lateefah to say goodbye to her high school chemistry students, she is excited to work with the next generation of scientists and researchers at our Learning Lab!

For many job candidates, understanding a company’s commitment to inclusion, diversity and equity is a critical part of the decision-making process. Our Vice President of Talent and Inclusion, Diversity and Equity, Diana Cruz Solash, spoke to BioSpace about how candidates can assess a company’s efforts during a job search. 
 
Some takeaways: 
- Check if the job description mentions/reflects the company’s commitment to inclusion, diversity and equity
- Look for signs that the company actively promotes belonging, community building, and professional development for all employees, e.g., through employee resource groups and career development programs
- See if interviewers bring up inclusion, diversity and equity without being prompted — if not, ask about it and listen closely for how those commitments are embedded in the way that people work with each other and in how the company operates
 
Read more perspective from Diana, including on how Vertex reinforces our inclusion, diversity and equity commitment in interviews and in day-to-day working life: https://lnkd.in/ehCbeFXV

Our Vertexians are celebrating the recent news of FDA approval of our gene-edited treatment for #BetaThalassemia. Vertexian Yamila reflects on what this moment means:

“Often, patients are seeing medical providers who are not thalassemia specialists. So the patient is usually responsible for bringing in that knowledge and then advocating for themselves.” — Pranav Saha, a courageous advocate living with #BetaThalassemia 
 
Hear Pranav break down the importance of self-advocacy for people living with beta thalassemia:

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia. We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: https://lnkd.in/gBBrWdnK

“Our patients always inspire us to never give up.” Paul Negulescu, Senior Vice President, Research, reflects on the last two decades of our drug discovery process and taking on new challenges.

We’re celebrating the extraordinary life, values and legacy of Dr. Martin Luther King, Jr.  

A transformational leader and advocate for nonviolence and equal rights, Dr. King made an indelible impact in the United States and beyond — earning the Nobel Peace Prize in 1964 for his dedication to civil rights. 

#MLKDay is the only U.S. federal holiday designated as a National Day of Service, and the Vertex Foundation is supporting opportunities for Vertexians to give back in the communities in which we live and work.

We care for and care about our people. 

And we’re honored to be named a Best Adoption-Friendly Workplace by the Dave Thomas Foundation. A recognition that we don’t take lightly, we pride ourselves on offering comprehensive benefits that support families. 

Explore our family-building benefits like adoption, surrogacy and more: https://lnkd.in/e4yB6GNb

“’What if?’ is a powerful question,” says Andre Williams, Head of our Boston Learning Lab.
 
“Our STEAM education programs spark this question in our students by engaging them in hands-on scientific experiments as well as exposure to the wide variety of career paths in the biotech industry. Working with students in our local community makes me excited to see the next generation of scientists get their start.” 

#STEAM #SteamEducation  #STEMeducation #SteamEducator #STEM #HandsOn  #21stCenturySkills

The Saudi Food and Drug Authority (SFDA) approves our treatment for #SickleCellDisease and #BetaThalassemia in the Kingdom of Saudi Arabia. Learn more: https://lnkd.in/epWDX4Z6

CF Physio

CF GeneE for iPad

CFDaily EU

GPS Connect by Vertex

Science Day

CF GeneE

CFDaily

Domain Not Resolving

DNSSEC

Google Maps

Font Awesome

LetsEncrypt

Mobile Non Scaleable Content

nginx

Cloudflare CDN

Microsoft Exchange Online

IPv6

Founder, Career Coach

Alisia Engle

Vice President and CFO, International

Ashley Grist

Vice President, Chief Compliance Officer

Brian Barry

Chief Medical Officer & EVP, Global Medicines Development and Medical Affairs

Carmen Bozic

Owner

Catherine Westling

Chad Howard

Assistant General Counsel

Christiana Stevenson

Christy Safford

Co-Owner

Darshi Choubisa

Engineering

David M. Altshuler

Reshma Kewalramani

Dennis Winger

Alan Garber

H. Daniel Perez

Matthew Emmens

Lloyd Carney

Yuchun Lee

Elaine Ullian

President and Chief Executive Officer

Jeffrey Leiden

Executive Chairman

Nina Devlin

Senior Vice President and Chief Communications Officer

Ludovic Fenaux

Senior Vice President, International Commercial Operations

Megan Krench

Director of BD - External Innovation

Brian Goldman

Research Fellow

Mark Hollison

Procurement and Strategic Sourcing Director

John Gray

Senior Vice President, Genetic Therapies Research

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. 

Companies With More Than $1M in Revenue (Top 10K)

Massachusetts Companies With More Than 10 Employees (Top 10K)

Greater Boston Area Companies With More Than 500 Employees

United States Investors (Top 10K)

Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

Post-IPO Secondary - Vertex Pharmaceuticals

Post-IPO Equity - Vertex Pharmaceuticals

Post-IPO Debt - Vertex Pharmaceuticals

Venture Round - Vertex Pharmaceuticals

Boston

Massachusetts

United States

North America

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

M&A activity – CRISPR fuelling investor interest in gene editing

RBC's top 10 questions and answers on biotech stocks

Cystic Fibrosis Market Size to be Worth USD 55.4 Billion by 2032, with a Projected CAGR of 21.6%

Five S&P 500 Stocks On This Elite IBD List Near Buy Points

2 Biotech Stocks You Can Buy Hand Over Fist This Month

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms

Treasury's $58 B 3-year auction was terrible

Vertex Pharmaceuticals develops medicines for cystic fibrosis, a genetic disease affecting the lungs and digestive system.

Vertex is involved in research and development of treatments for sickle cell disease, focusing on understanding patient experiences and advancing potential therapies.

Vertex is investigating cellular-level treatments for type 1 diabetes, aiming to develop innovative therapies.

Vertex is researching therapies for APOL1-mediated kidney disease, a genetic condition with significant unmet medical needs.

Vertex has been researching potential medicines to treat pain for over 20 years, focusing on innovative approaches.

Vertex is committed to developing treatments for beta thalassemia, a blood disorder, through ongoing research and community engagement.

United Kingdom

Europe

Austria

South Korea

Asia

Germany

HTML5

Google Tag Manager

Google Analytics

Adobe Flash

Akamai Intelligent Platform

Facebook

Fonts.com

Vimeo

DigiCert

Bootstrap

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

news impact assignment basic	general
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	407b3b5c
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	6bd2210c
crunchbase profile	general	Nov 22, 2024 8:45 AM	da03d101
li profile	general	Jan 31, 2024 7:55 PM	1ac36480
translate crunchbase fundingrounds	general	Nov 22, 2024 10:59 AM	8a0d131d
peers	general
news basic	general	Dec 4, 2024 2:13 PM	51716795
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VRTX

Vertex Pharmaceuticals Incorporated

Last Close

450.37

22/11 21:00

Market Cap

126.86B

Beta: -

Volume Today

1.27M

Avg: -